[{"id":"62108e74-4662-481f-afc9-1a0b17537745","acronym":"NCI-2019-04325","url":"https://clinicaltrials.gov/study/NCT04073745","created_at":"2025-03-03T09:56:16.669Z","updated_at":"2025-03-03T09:56:16.669Z","phase":"Phase 1","brief_title":"Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04073745 - NCI-2019-04325","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IL2RA • CD4 • FOXP3 • ISG20","pipe":"","alterations":" ","tags":["IL2RA • CD4 • FOXP3 • ISG20"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/04/2019","start_date":" 12/04/2019","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-28"},{"id":"d69d9e8b-481b-4b6a-a241-66952601f3da","acronym":"RITZ","url":"https://clinicaltrials.gov/study/NCT05735834","created_at":"2023-02-21T16:01:53.200Z","updated_at":"2025-02-25T14:03:19.754Z","phase":"Phase 3","brief_title":"Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients","source_id_and_acronym":"NCT05735834 - RITZ","lead_sponsor":"International Extranodal Lymphoma Study Group (IELSG)","biomarkers":" MYD88 • CCND1 • BCL6 • IL2RA • MME • ITGAE • ISG20","pipe":" | ","alterations":" IL2RA expression","tags":["MYD88 • CCND1 • BCL6 • IL2RA • MME • ITGAE • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Brukinsa (zanubrutinib) • Truxima (rituximab-abbs)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/21/2024","start_date":" 05/21/2024","primary_txt":" Primary completion: 05/01/2029","primary_completion_date":" 05/01/2029","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-02-19"},{"id":"c6706368-4b51-4cd8-9e6f-57a4d3ecf646","acronym":"","url":"https://clinicaltrials.gov/study/NCT01526096","created_at":"2021-01-18T06:26:01.906Z","updated_at":"2025-02-25T16:43:39.104Z","phase":"Phase 1","brief_title":"Stem Cell Transplantation for Patients With Multiple Myeloma","source_id_and_acronym":"NCT01526096","lead_sponsor":"University of Chicago","biomarkers":" IL2RA • CD4 • FOXP3 • ISG20","pipe":"","alterations":" ","tags":["IL2RA • CD4 • FOXP3 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • plerixafor"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 07/12/2011","start_date":" 07/12/2011","primary_txt":" Primary completion: 09/12/2025","primary_completion_date":" 09/12/2025","study_txt":" Completion: 09/12/2025","study_completion_date":" 09/12/2025","last_update_posted":"2025-02-05"},{"id":"53f4eddd-132e-4531-8be4-d3f2264f7d40","acronym":"","url":"https://clinicaltrials.gov/study/NCT06790797","created_at":"2025-02-25T18:39:59.893Z","updated_at":"2025-02-25T18:39:59.893Z","phase":"","brief_title":"Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients","source_id_and_acronym":"NCT06790797","lead_sponsor":"Zhao Jun","biomarkers":" CD8 • IFNG • IL2RA • CD4 • CD69 • TNFRSF9 • FOXP3 • ENTPD1","pipe":"","alterations":" ","tags":["CD8 • IFNG • IL2RA • CD4 • CD69 • TNFRSF9 • FOXP3 • ENTPD1"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/12/2023","start_date":" 02/12/2023","primary_txt":" Primary completion: 07/30/2027","primary_completion_date":" 07/30/2027","study_txt":" Completion: 07/30/2027","study_completion_date":" 07/30/2027","last_update_posted":"2025-01-24"},{"id":"10e7c484-a234-4aa3-b3ff-69b3ed1da252","acronym":"CA209-324","url":"https://clinicaltrials.gov/study/NCT02648997","created_at":"2024-01-24T15:18:16.455Z","updated_at":"2025-02-25T14:36:04.275Z","phase":"Phase 2","brief_title":"An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma","source_id_and_acronym":"NCT02648997 - CA209-324","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" PD-L1 • PD-1 • IL2RA • CD4 • CD69 • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1 • IL2RA • CD4 • CD69 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-12-19"},{"id":"7d9b53ef-b645-44ee-9c8e-8c8c3875b0f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06569485","created_at":"2025-02-26T12:22:38.642Z","updated_at":"2025-02-26T12:22:38.642Z","phase":"Phase 2","brief_title":"A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients","source_id_and_acronym":"NCT06569485","lead_sponsor":"Sun Yat-sen University","biomarkers":" CD8 • IFNG • CDK4 • IL2RA • CD4 • IL2 • FOXP3 • IL17A • ISG20","pipe":"","alterations":" ","tags":["CD8 • IFNG • CDK4 • IL2RA • CD4 • IL2 • FOXP3 • IL17A • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Cosela (trilaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 05/23/2024","start_date":" 05/23/2024","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-08-26"},{"id":"114d9c89-e0e5-473e-a324-f2022f9b4244","acronym":"","url":"https://clinicaltrials.gov/study/NCT04465643","created_at":"2021-01-18T21:27:49.677Z","updated_at":"2025-02-25T14:29:26.270Z","phase":"Phase 1","brief_title":"Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor","source_id_and_acronym":"NCT04465643","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20","pipe":"","alterations":" ","tags":["PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/08/2021","start_date":" 06/08/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-06-21"},{"id":"54b0572b-d8fb-48d8-acfb-e6927b1cd7aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT03912064","created_at":"2021-01-18T19:15:12.856Z","updated_at":"2024-07-02T16:34:27.453Z","phase":"Phase 1","brief_title":"A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT","source_id_and_acronym":"NCT03912064","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" IL2RA • ISG20","pipe":"","alterations":" ","tags":["IL2RA • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • CD25hi Treg depleted DLI"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 07/10/2019","start_date":" 07/10/2019","primary_txt":" Primary completion: 05/24/2024","primary_completion_date":" 05/24/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-11"},{"id":"f003bb6c-5459-49c1-947d-35ec28b1d2c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04135079","created_at":"2024-02-23T15:25:03.657Z","updated_at":"2024-07-02T16:35:04.833Z","phase":"","brief_title":"Immune Profiling in Multiple Myeloma","source_id_and_acronym":"NCT04135079","lead_sponsor":"Mario Boccadoro","biomarkers":" PD-1 • IFNG • IL6 • TNFA • IL2RA • ICOS • IL10 • CD27 • ICOSLG • TGFB1 • CD31 • IL17A • IL1B • PECAM1 • CD86","pipe":"","alterations":" ","tags":["PD-1 • IFNG • IL6 • TNFA • IL2RA • ICOS • IL10 • CD27 • ICOSLG • TGFB1 • CD31 • IL17A • IL1B • PECAM1 • CD86"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/15/2019","start_date":" 04/15/2019","primary_txt":" Primary completion: 04/28/2021","primary_completion_date":" 04/28/2021","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-05-08"},{"id":"8e76549d-af11-4f1e-8e81-eb9a8a62b421","acronym":"NCI-2017-01950","url":"https://clinicaltrials.gov/study/NCT03348748","created_at":"2024-05-11T04:28:26.434Z","updated_at":"2024-07-02T16:35:05.635Z","phase":"Phase 1","brief_title":"Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03348748 - NCI-2017-01950","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CD8 • IL2RA • CD4 • FOXP3 • ISG20","pipe":"","alterations":" ","tags":["CD8 • IL2RA • CD4 • FOXP3 • ISG20"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/18/2017","start_date":" 12/18/2017","primary_txt":" Primary completion: 07/12/2021","primary_completion_date":" 07/12/2021","study_txt":" Completion: 10/08/2025","study_completion_date":" 10/08/2025","last_update_posted":"2024-05-07"},{"id":"1d4dd198-7dd9-44b5-bf2f-70642e346bc2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06400160","created_at":"2024-05-11T04:34:11.020Z","updated_at":"2024-07-02T16:35:05.740Z","phase":"Phase 1/2","brief_title":"Clinical Trial of TB511 in Advanced Solid Tumors","source_id_and_acronym":"NCT06400160","lead_sponsor":"Twinpig Biolab, Inc.","biomarkers":" CD8 • IFNG • TNFA • IL2RA • CD163 • PTPRC • IL2 • NCAM1 • IL10 • GZMB • ITGB2","pipe":" | ","alterations":" IL2-L","tags":["CD8 • IFNG • TNFA • IL2RA • CD163 • PTPRC • IL2 • NCAM1 • IL10 • GZMB • ITGB2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-05-06"},{"id":"a2dce45d-64bf-4128-876e-4a25b3b1a037","acronym":"","url":"https://clinicaltrials.gov/study/NCT01059786","created_at":"2021-01-18T04:10:26.425Z","updated_at":"2024-07-02T16:35:06.574Z","phase":"Phase 2","brief_title":"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia","source_id_and_acronym":"NCT01059786","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD22 • IL2RA • ITGAE • ITGAX • ISG20","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD22 • IL2RA • ITGAE • ITGAX • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • pentostatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 12/15/2022","primary_completion_date":" 12/15/2022","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-01"},{"id":"8a617f1a-04a1-44fa-9406-0c4b9b9170e3","acronym":"BEAUTY","url":"https://clinicaltrials.gov/study/NCT03979508","created_at":"2021-01-18T19:34:12.469Z","updated_at":"2024-07-02T16:35:07.182Z","phase":"Phase 2","brief_title":"Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer","source_id_and_acronym":"NCT03979508 - BEAUTY","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1","pipe":" | ","alterations":" JAK2 amplification","tags":["HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-04-29"},{"id":"90515a21-3e57-41de-96be-20611fb49d4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05065554","created_at":"2021-10-04T12:52:56.869Z","updated_at":"2025-02-25T15:00:05.879Z","phase":"Phase 2","brief_title":"ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy","source_id_and_acronym":"NCT05065554","lead_sponsor":"Shayna Sarosiek, MD","biomarkers":" CD20 • CD22 • IL2RA • CD5 • SDC1 • CD27 • MME • ITGAE • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD22 • IL2RA • CD5 • SDC1 • CD27 • MME • ITGAE • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 11/16/2021","start_date":" 11/16/2021","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2024-04-17"},{"id":"313cce70-347b-44fa-8592-5bfdfa424f9b","acronym":"HSBRT2402","url":"https://clinicaltrials.gov/study/NCT06313190","created_at":"2024-03-15T21:36:53.401Z","updated_at":"2024-07-02T16:35:14.523Z","phase":"Phase 2","brief_title":"Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)","source_id_and_acronym":"NCT06313190 - HSBRT2402","lead_sponsor":"Sun Yat-sen University","biomarkers":" IL6 • IL2RA • CD40","pipe":"","alterations":" ","tags":["IL6 • IL2RA • CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 04/05/2024","start_date":" 04/05/2024","primary_txt":" Primary completion: 04/30/2028","primary_completion_date":" 04/30/2028","study_txt":" Completion: 04/30/2030","study_completion_date":" 04/30/2030","last_update_posted":"2024-03-15"},{"id":"0f4f4db7-864a-4af4-9ed3-894c0ed55bd1","acronym":"HSBRT2401","url":"https://clinicaltrials.gov/study/NCT06261125","created_at":"2024-02-15T17:26:46.872Z","updated_at":"2024-07-02T16:35:15.217Z","phase":"Phase 2","brief_title":"Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)","source_id_and_acronym":"NCT06261125 - HSBRT2401","lead_sponsor":"Mian XI","biomarkers":" IL6 • IL2RA • CD40","pipe":"","alterations":" ","tags":["IL6 • IL2RA • CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • AiRuiLi (adebrelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/10/2024","start_date":" 03/10/2024","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-03-12"},{"id":"adb47411-e4ca-44c0-af22-a98798c3a97a","acronym":"EC-CRT-007","url":"https://clinicaltrials.gov/study/NCT06187597","created_at":"2024-01-02T14:16:57.201Z","updated_at":"2024-07-02T16:35:15.221Z","phase":"Phase 2","brief_title":"Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)","source_id_and_acronym":"NCT06187597 - EC-CRT-007","lead_sponsor":"Sun Yat-sen University","biomarkers":" IL6 • CTLA4 • IL2RA • NCAM1 • CD68 • CD40","pipe":"","alterations":" ","tags":["IL6 • CTLA4 • IL2RA • NCAM1 • CD68 • CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-03-12"},{"id":"c80dda17-2bdc-4783-9fe5-a49313fb46d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05139004","created_at":"2021-12-01T15:53:46.640Z","updated_at":"2024-07-02T16:35:21.820Z","phase":"Phase 1","brief_title":"90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT05139004","lead_sponsor":"City of Hope Medical Center","biomarkers":" FLT3 • NPM1 • IL2RA • ISG20","pipe":" | ","alterations":" MLL rearrangement • IL2RA expression • Chr t(9;11)","tags":["FLT3 • NPM1 • IL2RA • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • IL2RA expression • Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • fludarabine IV • Kepivance (palifermin)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 07/19/2022","start_date":" 07/19/2022","primary_txt":" Primary completion: 12/13/2024","primary_completion_date":" 12/13/2024","study_txt":" Completion: 12/13/2024","study_completion_date":" 12/13/2024","last_update_posted":"2024-01-30"},{"id":"f9e8a0b7-2582-42c3-ba42-3a60ab5f129f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04323202","created_at":"2024-01-18T18:18:19.652Z","updated_at":"2024-07-02T16:35:23.036Z","phase":"Phase 1","brief_title":"Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H\u0026N","source_id_and_acronym":"NCT04323202","lead_sponsor":"Brian Gastman","biomarkers":" CD8 • PD-1 • LAG3 • IL2RA • TIGIT • CD4 • FASLG • CD27 • FOXP3 • ISG20","pipe":"","alterations":" ","tags":["CD8 • PD-1 • LAG3 • IL2RA • TIGIT • CD4 • FASLG • CD27 • FOXP3 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 08/04/2020","start_date":" 08/04/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-01-18"},{"id":"266a2712-9c1f-4bc2-b88c-002f9d951d7d","acronym":"GOG-3039","url":"https://clinicaltrials.gov/study/NCT04393285","created_at":"2023-12-13T16:16:37.842Z","updated_at":"2024-07-02T16:35:26.346Z","phase":"Phase 2","brief_title":"Abemaciclib and Letrozole to Treat Endometrial Cancer","source_id_and_acronym":"NCT04393285 - GOG-3039","lead_sponsor":"Gynecologic Oncology Group","biomarkers":" ER • CDKN2A • RB1 • CD8 • PD-1 • CCND1 • CCNE1 • CDK4 • CTLA4 • IL2RA • CDK6 • PTPRC • FOXP3 • CCNE2 • ISG20","pipe":" | ","alterations":" CCND1 expression • CCND1 mutation","tags":["ER • CDKN2A • RB1 • CD8 • PD-1 • CCND1 • CCNE1 • CDK4 • CTLA4 • IL2RA • CDK6 • PTPRC • FOXP3 • CCNE2 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression • CCND1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • letrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 10/10/2020","start_date":" 10/10/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-13"},{"id":"0f0997b4-e016-4774-9c8c-8817ae0fe8c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05462496","created_at":"2022-07-18T14:01:45.193Z","updated_at":"2024-07-02T16:35:28.767Z","phase":"Phase 2","brief_title":"Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer","source_id_and_acronym":"NCT05462496","lead_sponsor":"Icahn School of Medicine at Mount Sinai","biomarkers":" CD38 • IL2RA • CD69 • ISG20","pipe":"","alterations":" ","tags":["CD38 • IL2RA • CD69 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 3","initiation":"Initiation: 03/13/2023","start_date":" 03/13/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-11-18"},{"id":"35641ab2-6f4d-40e3-8334-a2f46e81a6fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05020912","created_at":"2021-08-25T14:53:19.986Z","updated_at":"2024-07-02T16:35:29.739Z","phase":"Phase 2","brief_title":"Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy","source_id_and_acronym":"NCT05020912","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" PD-L1 • CD8 • LAG3 • CTLA4 • HAVCR2 • IL2RA • CD33 • TIGIT • CD4 • IL7R • NCAM1 • S100A9 • FOXP3","pipe":" | ","alterations":" LAG3 expression","tags":["PD-L1 • CD8 • LAG3 • CTLA4 • HAVCR2 • IL2RA • CD33 • TIGIT • CD4 • IL7R • NCAM1 • S100A9 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LAG3 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 12/13/2021","start_date":" 12/13/2021","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2023-11-09"},{"id":"f13f9d98-9d60-4ad6-8b7d-183c14dad4ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT03607370","created_at":"2021-01-18T17:44:02.029Z","updated_at":"2024-07-02T16:35:29.959Z","phase":"","brief_title":"Timing for Rectal Surgery After Chemoradiotherapy","source_id_and_acronym":"NCT03607370","lead_sponsor":"National Cancer Institute, Lithuania","biomarkers":" IL6 • IL2RA • IL10 • IL1B","pipe":"","alterations":" ","tags":["IL6 • IL2RA • IL10 • IL1B"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 142","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-11-08"},{"id":"5206abc5-f3bf-41df-978b-3fe0011087ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT05504408","created_at":"2022-08-17T13:55:03.907Z","updated_at":"2024-07-02T16:35:34.127Z","phase":"","brief_title":"Observational Study for the Evaluation of Incidence of Systemic Mastocytosis in t(8;21) Acute Myeloid Leukemia","source_id_and_acronym":"NCT05504408","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" TNFRSF8 • IL2RA • CD2 • ISG20","pipe":" | ","alterations":" TNFRSF8 expression • IL2RA expression","tags":["TNFRSF8 • IL2RA • CD2 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression • IL2RA expression"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2023-10-10"}]